Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to proposed mergers and acquisitions. The firm is examining whether McCormick & Company's merger with Unilever's Foods business, Odyssey Marine Exploration's merger with American Ocean Minerals Corporation, Soleno Therapeutics' sale to Neurocrine Biosciences, and Forian Inc.'s sale to a consortium led by its CEO are providing fair consideration to shareholders. The firm suggests insiders may receive substantial benefits unavailable to ordinary shareholders and seeks increased consideration and additional disclosures on behalf of investors.

McCormick & Company declared a quarterly dividend of $0.48 per share, payable April 27, 2026, marking the 102nd consecutive year of dividend payments. The global flavor company, with approximately $7 billion in annual sales across 150 countries, manufactures and distributes herbs, spices, seasonings, and flavors through its Consumer and Flavor Solutions segments.

A major M&A week sees Sysco acquiring Restaurant Depot for $26 billion and McCormick merging with Unilever's food division for $44 billion, while Eli Lilly acquires Centessa Pharmaceuticals for $7.8 billion. The podcast discusses the track record of consumer brand mergers (mostly unsuccessful) and analyzes Whirlpool as a dividend investment amid housing market headwinds.

The global marinades market is projected to grow from US$12.35 billion in 2024 to US$18.44 billion by 2031, with a CAGR of 5.9%. Growth is driven by rising consumer demand for convenience foods, clean-label ingredients, and global cuisines. Asia Pacific leads the market, while food manufacturing remains the dominant segment. However, rising raw material costs present a significant challenge.

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws and breaches of fiduciary duties. The investigations concern Soleno Therapeutics' sale to Neurocrine Biosciences, Forian's sale to a consortium led by its CEO, McCormick & Company's merger with Unilever's Foods business, and Cyclerion Therapeutics' merger with Korsana Biosciences. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.

Major M&A activity dominates the market with McCormick merging with Unilever's Foods business in a $29.1 billion deal, Sysco acquiring Jetro Restaurant Depot for $29 billion, and Eli Lilly acquiring Centessa Pharmaceuticals for $7.8 billion. Meanwhile, QVC faces financial distress and is considering Chapter 11 bankruptcy, while several other companies including IO Biotech and Lipella Pharmaceuticals have filed for bankruptcy.

McCormick is acquiring Unilever's food business for $45 billion in a major consolidation of the condiments and seasonings market. McCormick shareholders will own 35% of the new combined entity. While the deal offers strategic benefits including cost synergies of $600 million and improved margins, Wall Street reacted negatively with McCormick stock falling 6.1% on announcement day. The deal faces typical merger risks including integration challenges and culture clashes, with closure expected by mid-2027.

U.S. stock markets rallied on March 31, 2026, with the S&P 500 gaining 2.91%, Nasdaq surging 3.83%, and the Dow climbing 2.49% following hopes of de-escalation in the Iran conflict. Big-tech stocks led gains, while energy stocks have significantly outperformed tech year-to-date. Analysts suggest tech stocks may present buying opportunities as risk sentiment improves.

McCormick & Company's stock has declined to attractive valuation levels near $50 and 16X earnings multiple due to concerns about its planned $45 billion merger with Unilever's food business. Despite near-term execution risks and dilution concerns, the company reported strong Q1 results with 16.7% revenue growth and 10% earnings growth. The acquisition presents significant long-term value creation potential, with the combined entity becoming one of the largest flavor-focused companies globally, supported by McCormick's reliable 40-year dividend growth history.

McCormick is acquiring Unilever's food business in a $45 billion deal, combining McCormick's spice portfolio with Unilever's brands like Hellmann's and Knorr. The merger is expected to create a $20+ billion revenue company with $600 million in cost savings, accelerated growth to 3-5% annually, and enhanced profitability. However, the deal carries integration risks and will initially result in a 4.0x leverage ratio, though the company aims to deleverage to 3.0x within two years.

U.S. equities staged their strongest rally in weeks on Tuesday following Trump's signals of willingness to end military hostilities with Iran. The S&P 500 advanced 1.8% to 6,456, though it remains down 6.2% for the month. Tech stocks led the recovery with the Nasdaq 100 rising 2%. Despite the rally, the S&P 500 is on track for its worst monthly performance since September 2022.

McCormick & Co shares fell 5.30% to a 52-week low despite beating Q1 earnings expectations, as investors expressed concerns about the company's $44.8 billion merger with Unilever's food business. The deal involves a $15.7 billion cash payout and will result in Unilever shareholders owning 55.1% of the combined company, raising concerns about debt load and equity dilution.